Pembrolizumab
RG1003718
Phase 2 mab terminated
Quick answer
Pembrolizumab for Hodgkin's Lymphoma is a Phase 2 program (mab) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Hodgkin's Lymphoma
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated